GNI Group Ltd. (JP:2160)
:2160
Top Page
GNI Group
(2160)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥3,339.00
▲(5.00% Upside)
Action:ReiteratedDate:03/07/26
The score is primarily held back by weak recent fundamentals—2025 losses and two years of negative operating/free cash flow—despite a comparatively strong balance sheet. Technicals are a key offset with clear upward trend and positive momentum. Valuation is penalized because losses make the P/E less informative and there is no dividend support.
Positive Factors
Balance sheet strength
Low leverage and materially higher equity provide lasting financial resilience, improving the company’s ability to fund R&D, weather clinical or commercialization delays, and pursue strategic partnerships or licensing without immediate refinancing. This underpins multi‑quarter execution flexibility.
Negative Factors
Negative operating and free cash flow
Two consecutive years of cash burn reduce self‑funding capacity and raise reliance on external financing, which can dilute shareholders or constrain R&D/commercial investment. Persistent negative cash flow elevates execution and funding risk over the medium term until cash generation recovers.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Low leverage and materially higher equity provide lasting financial resilience, improving the company’s ability to fund R&D, weather clinical or commercialization delays, and pursue strategic partnerships or licensing without immediate refinancing. This underpins multi‑quarter execution flexibility.
Read all positive factors
GNI Group (2160) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥177.12B
Dividend YieldN/A
Average Volume (3M)969.16K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth13.78%
EPS Growth-110.02%
CountryJP
Employees867
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-74.44
Shares Outstanding55,698,696
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside19.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥33.25B
GNI Group Business Overview & Revenue Model
Company Description
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company i...
How the Company Makes Money
GNI Group generates revenue through the development, manufacturing, and commercialization of pharmaceutical products, including therapies for respiratory and fibrotic diseases. Its revenues primarily come from the sales of its drug products, licen...
GNI Group Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
74
Positive
Cash Flow
35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 26.84B | 23.61B | 26.01B | 17.42B | 12.69B |
| Gross Profit | 19.99B | 18.04B | 22.43B | 14.74B | 11.09B |
| EBITDA | -1.17B | 436.69M | 5.19B | 1.76B | 1.50B |
| Net Income | -4.41B | 1.10B | 8.09B | 388.83M | 1.07B |
Balance Sheet | |||||
| Total Assets | 83.79B | 71.94B | 64.27B | 33.91B | 30.30B |
| Cash, Cash Equivalents and Short-Term Investments | 21.10B | 12.93B | 23.15B | 11.24B | 14.35B |
| Total Debt | 5.37B | 22.66B | 18.84B | 537.36M | 1.13B |
| Total Liabilities | 32.11B | 32.07B | 27.72B | 14.10B | 11.03B |
| Stockholders Equity | 50.15B | 36.45B | 33.79B | 20.97B | 18.86B |
Cash Flow | |||||
| Free Cash Flow | -2.74B | -3.69B | 5.28B | -580.20M | 172.78M |
| Operating Cash Flow | -2.41B | -3.16B | 6.55B | 393.32M | 552.27M |
| Investing Cash Flow | 2.73B | -12.89B | -3.33B | -4.12B | 2.24B |
| Financing Cash Flow | 10.47B | 3.22B | 7.17B | -646.33M | 357.06M |
GNI Group Technical Analysis
Positive
3180.00
Price Trends
2956.58
Positive
2712.50
Positive
2746.13
Positive
Market Momentum
40.49
Positive
52.92
Neutral
73.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2160, the sentiment is Positive. The current price of 3180 is above the 20-day moving average (MA) of 3087.30, above the 50-day MA of 2956.58, and above the 200-day MA of 2746.13, indicating a bullish trend. The MACD of 40.49 indicates Positive momentum. The RSI at 52.92 is Neutral, neither overbought nor oversold. The STOCH value of 73.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2160.
GNI Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ¥177.12B | -28.68 | -10.40% | ― | 13.78% | -110.02% | |
52 Neutral | ¥137.39B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.20B | -34.16 | ― | ― | -5.65% | -469.19% | |
48 Neutral | ¥92.40B | -5.96 | -19.31% | ― | -1.96% | -64.18% | |
46 Neutral | ¥157.22B | -57.13 | -10.16% | ― | -62.47% | -134.06% | |
43 Neutral | ¥154.90B | -35.18 | -253.07% | ― | ― | -12.69% |
* Healthcare Sector Average
JP:2160
GNI Group
3,180.00
1,364.00
75.11%
JP:4587
Peptidream
1,211.00
-679.50
-35.94%
JP:4592
SanBio Co
1,985.00
-15.00
-0.75%
JP:4565
Sosei Group
1,021.00
281.00
37.97%
JP:4974
Takara Bio Inc.
1,141.00
360.00
46.09%
JP:7774
Japan Tissue Engineering Co., Ltd.
596.00
151.00
33.93%
GNI Group Corporate Events
GNI Group Issues Revenue-Only Forecast for 2026 Amid Regulatory Uncertainty
Apr 1, 2026
GNI Group has for the first time released a revenue forecast for the fiscal year ending December 31, 2026, projecting consolidated sales of ¥27.2 billion based on existing businesses that are not contingent on regulatory outcomes. The guidanc...
GNI Group Maintains Core Leadership, Adds New Outside Director After AGM
Mar 26, 2026
GNI Group has reaffirmed its leadership structure following the 25th Annual General Meeting of Shareholders held on March 26, 2026. Ying Luo was reappointed as director and continues as representative executive officer, president and CEO, while ke...
GNI Group Showcases Leadership in Fibrosis Therapies With Key China Designations
Mar 26, 2026
GNI Group has highlighted its core strengths in developing novel therapies for fibrotic conditions, led by its flagship product Etuary (pirfenidone) for pulmonary fibrosis, the first Class 1.1 new drug approved in China. The company also emphasize...
GNI Group Moves Closer to Commercialization With China NDA for Liver Fibrosis Drug F351
Mar 24, 2026
GNI Group’s U.S. affiliate Gyre Therapeutics has submitted a New Drug Application in China for F351, the group’s lead candidate for treating liver fibrosis caused by chronic hepatitis B. The filing with the National Medical Products Ad...
GNI Group Wins Priority Review in China for Hepatitis B–Related Liver Fibrosis Drug
Mar 18, 2026
GNI Group’s subsidiary Gyre Therapeutics has secured Priority Review designation from China’s National Medical Products Administration for F351, a drug candidate targeting liver fibrosis caused by chronic hepatitis B. The designation f...
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen
Mar 13, 2026
GNI Group, through its U.S. affiliate Gyre Therapeutics, outlined substantial revenue potential from its liver fibrosis drug Hydronidone (F351), estimating up to hundreds of millions of dollars in annual sales within five years and highlighting su...
GNI Group Revises Parent-Only Results After Tax and Valuation Adjustments
Mar 4, 2026
GNI Group Ltd. has announced corrections to previously disclosed non-consolidated financial results for the fiscal year ended December 31, 2025, after determining that tax expenses related to Controlled Foreign Corporation taxation for its wholly ...
GNI Group Revamps Board Slate With New Independent Director Ahead of AGM
Mar 4, 2026
GNI Group Ltd. has proposed a slate of director candidates for approval at its 25th Annual General Meeting of Shareholders on March 26, 2026, including the reappointment of President and CEO Ying Luo and key executive director Ryosuke Matsui. The ...
GNI Group Revises FY2025 Results After Overstated CFC Tax Expense
Mar 4, 2026
GNI Group has announced a partial correction to its consolidated financial results for fiscal 2025 after discovering that tax expenses related to Controlled Foreign Company taxation for its wholly owned subsidiary GNI Hong Kong Limited had been ov...
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal
Mar 3, 2026
GNI Group’s Nasdaq-listed subsidiary Gyre Therapeutics has agreed to acquire fellow GNI consolidated unit Cullgen Inc. in an all-stock deal valued at about $300 million, making Cullgen a wholly owned subsidiary. The combined business will op...
GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit
Feb 13, 2026
GNI Group Ltd., a biopharmaceutical company listed on the TSE Growth market, reported a sharp year-on-year swing in its non-consolidated performance for the fiscal year ended December 31, 2025, under Japanese GAAP. The company’s standalone r...
GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base
Feb 13, 2026
GNI Group reported FY2025 consolidated revenue of ¥26.84 billion, up 13.7% year on year, but swung to an operating loss of ¥3.48 billion and a loss attributable to owners of the parent of ¥4.41 billion, reversing the prior year̵...
GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty
Feb 13, 2026
GNI Group has postponed the disclosure of its full-year 2026 consolidated earnings forecast and related earnings presentation materials, as well as an earnings briefing that had been scheduled for February 24, 2026. The company cites both regulato...
GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy
Feb 12, 2026
GNI Group has addressed a series of investor questions to enhance transparency around its strategy and disclosure practices, notably regarding the planned acquisition of Gyre Pharmaceuticals funded by its July 2025 overseas offering. The company a...
GNI Group Slashes 2025 Profit Outlook as Cullgen Listing Is Delayed and Impairment Losses Loom
Jan 23, 2026
GNI Group has sharply revised its full-year 2025 consolidated earnings forecast, now projecting lower revenue of ¥26.8 billion and a swing from a previously expected substantial profit to a net loss, driven mainly by the deferral of the plann...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.